The European Medicines Agency has added Guillain-Barré syndrome to its list of possible side effects after receiving the Covid-19 vaccine AstraZeneca.
Specifically, Reuters reported that the European Medicines Agency (EMA) on September 9 added a rare side effect in people receiving the AstraZeneca vaccine. However, the RMA asserts that the benefits of vaccination still outweigh the potential side effects.
After the EMA studied and analyzed 833 cases of Guillain-Barré syndrome out of a total of 529 million people who received the Covid-19 vaccine worldwide, as of July 31. The unit concluded that there is a cause-and-effect relationship between the AstraZeneca vaccine and Guillain-Barré syndrome, and this relationship is known as Vaxzevria.
The agency also said the side effect was “very rare”, the frequency of people receiving the AstraZeneca vaccine experiencing the lowest of the possible side effects.
Related to this syndrome, the US Food and Drug Administration (FDA) has also previously added a warning about possible side effects in people receiving Johnson & Johnson’s Covid-19 vaccine. Guillain-Barré.
Accordingly, two vaccines Johnson & Johnson and AstraZeneca both use virus vector technology. Specifically, instead of sending the DNA sequence of the spike protein into the cell epidemic region – where the virus produces the spike protein – on the outer envelope of SARS-CoV-2, these two vaccines will enter the cell nucleus.
Certain parts of the spike protein, once inside the cell nucleus, will bind or separate, thereby creating mutant versions, unable to bind to the cell membrane to induce immunity.
According to medicine, Guillain-Barré syndrome is a rare disorder in which the immune system attacks the nerves of the human body. The first symptoms of Guillain-Barré syndrome are muscle weakness, paresthesias of the extremities, then spreading, even the whole body will be paralyzed. And people with this syndrome need to be hospitalized for prompt treatment.
Đọc bài viết bằng Tiếng Việt tại đây